Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
boston
5
×
boston blog main
life sciences
boston top stories
national blog main
clinical trials
deals
national top stories
san francisco blog main
startups
480 biomedical
abbvie
allergan
ally bridge group
alzheimer's disease
arsenal medical
azacitidine
beta-thalassemia
big data analytics
bioinnovation capital
biolabs
blackrock
bob langer
casdin capital
chemotherapy
chronic rhinosinusitis
covid-19
crispr
cynthia collins
dacogen
daraprim
decitabine
diabetic nephropathy
dna
drug delivery
drug pricing
drugs
editas medicine
epigenetics
What
biotech
5
×
medicines
new
company
developing
drug
genetic
ipo
million
public
raised
raises
research
therapeutics
abbvie
aims
alliance
analysis
approach
based
bio
bring
called
debut
debuts
develop
diseases
driving
drugs
editas
editing
employing
epigenetic
epigenetics
exits
experimental
field
flagship’s
gene
goldfinch
Language
unset
Current search:
biotech
×
boston
×
@xconomy.com
3 years ago
AbbVie Exits Editas Alliance, Pruning Another Genetic Medicines Pact
@xconomy.com
3 years ago
Goldfinch Raises $100M for Kidney Drug Studies Now, Perhaps an IPO Later
@xconomy.com
3 years ago
Lyra Therapeutics IPO Raises $56M for Tests of Tech for Runny Noses
@xconomy.com
4 years ago
Drug Pricing: Innovation, Investment, and the Public Good
@xconomy.com
4 years ago
Flagship’s Omega Aims to Take Epigenetic Drugs a Step Further
